Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by Fmr LLC

Fmr LLC reduced its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 11.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,678,527 shares of the company’s stock after selling 2,532,109 shares during the quarter. Fmr LLC owned approximately 9.11% of Taysha Gene Therapies worth $37,544,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Quantum Private Wealth LLC grew its holdings in shares of Taysha Gene Therapies by 4.6% in the second quarter. Quantum Private Wealth LLC now owns 730,520 shares of the company’s stock valued at $1,636,000 after purchasing an additional 32,000 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Taysha Gene Therapies during the second quarter worth $1,018,000. Principal Financial Group Inc. purchased a new stake in shares of Taysha Gene Therapies during the second quarter worth $48,000. Privium Fund Management B.V. acquired a new stake in shares of Taysha Gene Therapies in the second quarter valued at $213,000. Finally, Rhumbline Advisers purchased a new position in Taysha Gene Therapies in the second quarter valued at $413,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TSHA has been the topic of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Needham & Company LLC reiterated a “buy” rating and set a $6.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Canaccord Genuity Group increased their price objective on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Chardan Capital reaffirmed a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, November 14th. Finally, JMP Securities reissued a “market outperform” rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Price Performance

Shares of NASDAQ:TSHA opened at $2.48 on Monday. Taysha Gene Therapies, Inc. has a 12 month low of $1.19 and a 12 month high of $4.32. The firm has a market capitalization of $508.25 million, a P/E ratio of 3.94 and a beta of 0.79. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The company’s fifty day moving average price is $2.11 and its 200 day moving average price is $2.38.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.